Marshall Wace’s Alzamend Neuro ALZN Stock Holding History

Marshall Wace’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-92	Closed	-$154K	–	3382
2022 Q1	$154K	Sell	92 -29	-24%	-$54.5K	﹤0.01%	3139
2021 Q4	$313K	Buy	+121	New	+$374K	﹤0.01%	3017

Other funds holding ALZN

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCIA

Kingsbury Capital Investment Advisors Wilmette, Illinois $65.6M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Marshall Wace's ALZN Position: Q2 2022 in Review

Marshall Wace sold out of Alzamend Neuro (ALZN) in Q2 2022, closing a stake of 92 shares — an estimated $154K sold.

Marshall Wace first reported a position in ALZN in Q4 2021 and held it in 2 quarters. The position peaked at $313K in Q4 2021. 20 funds tracked by Wall St. Rank hold ALZN as of Q2 2022.

Marshall Wace reported no remaining Alzamend Neuro position as of Q2 2022 after selling out during the quarter.
Marshall Wace sold 92 Alzamend Neuro shares in Q2 2022, an estimated $154K.
Marshall Wace first reported a position in Alzamend Neuro in Q4 2021 and held it in 2 quarters.
Marshall Wace's Alzamend Neuro position peaked at $313K in Q4 2021.
20 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2022.

Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.